Brought to you by 
Knight licenses Monvantik/Moventig rights from AstraZeneca
20 Jan 2017
Executive Summary
AstraZeneca PLC granted Knight Therapeutics Inc. exclusive rights to sell Movantik (naloxegol) in Canada and Israel for opiate-induced constipation.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement